EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieKlinische Studie (Phase I)Open Access · CC BY-NC-ND 4.0

The Safety, Pharmacokinetics, and Antiviral Activity of ABI ‐4334, A Novel Next‐Generation Hepatitis B Capsid Assembly Modulator

Edward J Gane iD, Christian Schwabe, Nelli Ghicavii, Cristina Ticot iD, Katie Zomorodi, Steven J Knox iD, Kathryn M Kitrinos, Ran Yan iD, Jieming Liu, Grace Wang, Anuj Gaggar iD, Alina Jucov

Journal of Viral Hepatitis · 2026-12 · 33 (12)

DOI: 10.1111/jvh.70258 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Journal of Viral Hepatitis, online erschienen am 09.11.2026. Verfasst von Edward J Gane und 11 weiteren Autor:innen. Beteiligte Einrichtung: University of Auckland, Auckland, New Zealand. Hauptthemen laut MEDLINE: Antiviral Agents, Capsid, Hepatitis B virus, Hepatitis B, Chronic. Die Arbeit nennt 29 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Assembly Biosciences Inc..

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Novel, well‐tolerated, short‐term therapeutics for chronic hepatitis B virus infection (cHBV) are needed. ABI‐4334 is a next‐generation capsid assembly modulator that targets the HBV core protein. The safety, tolerability, and pharmacokinetics of ABI‐4334 in healthy volunteers and participants with cHBV and antiviral effects in participants with cHBV were examined in two Phase 1 studies. Study 101 was a placebo‐controlled study of healthy volunteers that included four single‐ascending dose cohorts and two once‐daily multiple‐ascending dose cohorts randomized 6:2 (ABI‐4334:placebo), and one crossover food‐effect cohort randomized 3:3 (fed:fasted). Study 102 was a randomized, blinded, placebo‐controlled study where participants with cHBV were randomized 8:2 (ABI‐4334 [2 dose cohorts]:placebo). Overall, 54 healthy volunteers and 20 participants with cHBV were included in Studies 101 and 102, respectively. Most participants (75%) in Study 102 were hepatitis B e antigen (HBeAg) negative and generally had lower baseline HBV DNA and pregenomic RNA (pgRNA) levels. ABI‐4334 was well tolerated, with no treatment‐emergent serious adverse events (AEs) or treatment‐emergent AEs leading to study discontinuation. The mean ABI‐4334 plasma half‐life ranges were comparable across doses in both studies. Following multiple‐dose administration in participants with cHBV, the steady‐state mean plasma half‐life ranged from 17.5 to 27.5 h. HBV DNA declines were observed in both HBeAg‐positive ( n = 3) and ‐negative ( n = 13) participants across doses. Reductions in pgRNA were observed in participants with detectable pgRNA at baseline. ABI‐4334 was well tolerated, with pharmacokinetics and antiviral results supporting the continued development of ABI‐4334 as a monotherapy or component of novel combination regimens for cHBV. Trial Registration: Study 101 (NCT05569941). Study 102 (NCT06384131)

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antiviral AgentsCapsidHepatitis B virusHepatitis B, ChronicVirus AssemblyAdolescentAdultFemaleHumansMaleMiddle AgedYoung AdultCross-Over StudiesDNA, ViralDouble-Blind MethodHealthy Volunteers

Stichwörter der Autor:innen

cccDNAchronic viral hepatitis Bhepatitis B virusviral capsid assembly

Substanzen

Antiviral AgentsDNA, Viral

Autor:innen und Institutionen

  • University of Auckland, Auckland, New Zealand.
  • New Zealand Clinical Research, Auckland, New Zealand.
  • ARENSIA Exploratory Medicine GmbH, Republican Clinical Hospital, Chișinău, Republic of Moldova.
  • Assembly Biosciences, Inc., South San Francisco, California, USA.
  • Department of Gastroenterology, Nicolae Testemițanu State University of Medicine and Pharmacy, Chișinău, Republic of Moldova.

ORCID-Profile: Edward J Gane, Cristina Ticot, Steven J Knox, Ran Yan, Anuj Gaggar

Förderung

  • Assembly Biosciences Inc.

Zitieren

APA

Gane, E. J., Schwabe, C., Ghicavii, N., Ticot, C., Zomorodi, K., Knox, S. J., Kitrinos, K. M., Yan, R., Liu, J., Wang, G., Gaggar, A., & Jucov, A. (2026). The Safety, Pharmacokinetics, and Antiviral Activity of ABI ‐4334, A Novel Next‐Generation Hepatitis B Capsid Assembly Modulator. Journal of Viral Hepatitis, 33(12). https://doi.org/10.1111/jvh.70258

Vancouver

Gane EJ, Schwabe C, Ghicavii N, Ticot C, Zomorodi K, Knox SJ, et al. The Safety, Pharmacokinetics, and Antiviral Activity of ABI ‐4334, A Novel Next‐Generation Hepatitis B Capsid Assembly Modulator. Journal of Viral Hepatitis. 2026;33(12). doi:10.1111/jvh.70258

BibTeX
@article{Gane2026,
  author = {Gane, Edward J and Schwabe, Christian and Ghicavii, Nelli and Ticot, Cristina and Zomorodi, Katie and Knox, Steven J and Kitrinos, Kathryn M and Yan, Ran and Liu, Jieming and Wang, Grace and Gaggar, Anuj and Jucov, Alina},
  title = {The Safety, Pharmacokinetics, and Antiviral Activity of ABI ‐4334, A Novel Next‐Generation Hepatitis B Capsid Assembly Modulator},
  journal = {Journal of Viral Hepatitis},
  year = {2026},
  volume = {33},
  number = {12},
  doi = {10.1111/jvh.70258}
}
Kostenlos starten →